RU2624238C2 - Лечение себореи - Google Patents
Лечение себореи Download PDFInfo
- Publication number
- RU2624238C2 RU2624238C2 RU2014126635A RU2014126635A RU2624238C2 RU 2624238 C2 RU2624238 C2 RU 2624238C2 RU 2014126635 A RU2014126635 A RU 2014126635A RU 2014126635 A RU2014126635 A RU 2014126635A RU 2624238 C2 RU2624238 C2 RU 2624238C2
- Authority
- RU
- Russia
- Prior art keywords
- scimnol
- ester
- pharmaceutically acceptable
- acceptable salt
- seborrhea
- Prior art date
Links
- 206010039792 Seborrhoea Diseases 0.000 title claims abstract description 24
- 208000008742 seborrheic dermatitis Diseases 0.000 title claims abstract description 24
- 150000002148 esters Chemical class 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 53
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 239000011734 sodium Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- 230000000699 topical effect Effects 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 6
- 230000002500 effect on skin Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000002374 sebum Anatomy 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 description 19
- 206010000496 acne Diseases 0.000 description 17
- 208000002874 Acne Vulgaris Diseases 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 7
- 210000001732 sebaceous gland Anatomy 0.000 description 7
- 241000251730 Chondrichthyes Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- -1 sulfuric acid ester Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241001490213 Milium Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000220304 Prunus dulcis Species 0.000 description 1
- 241000199690 Scymnus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000003581 cosmetic carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011905331 | 2011-12-20 | ||
| AU2011905331A AU2011905331A0 (en) | 2011-12-20 | Treatment of seborrhoea | |
| AU2012900670A AU2012900670A0 (en) | 2012-02-22 | Treatment of seborrhoea | |
| AU2012900670 | 2012-02-22 | ||
| PCT/AU2012/001543 WO2013090986A1 (en) | 2011-12-20 | 2012-12-14 | Treatment of seborrhoea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014126635A RU2014126635A (ru) | 2016-02-10 |
| RU2624238C2 true RU2624238C2 (ru) | 2017-07-03 |
Family
ID=48667492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014126635A RU2624238C2 (ru) | 2011-12-20 | 2012-12-14 | Лечение себореи |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20140364405A1 (enExample) |
| EP (1) | EP2793897B1 (enExample) |
| JP (1) | JP2015500841A (enExample) |
| KR (1) | KR20140120890A (enExample) |
| CN (1) | CN104144689A (enExample) |
| AU (1) | AU2012321108B2 (enExample) |
| BR (1) | BR112014014968A2 (enExample) |
| CA (1) | CA2859826A1 (enExample) |
| DK (1) | DK2793897T3 (enExample) |
| ES (1) | ES2632591T3 (enExample) |
| HU (1) | HUE033800T2 (enExample) |
| IN (1) | IN2014CN04693A (enExample) |
| MX (1) | MX2014007659A (enExample) |
| MY (1) | MY165030A (enExample) |
| PL (1) | PL2793897T3 (enExample) |
| PT (1) | PT2793897T (enExample) |
| RU (1) | RU2624238C2 (enExample) |
| SG (1) | SG11201403078RA (enExample) |
| WO (1) | WO2013090986A1 (enExample) |
| ZA (1) | ZA201404348B (enExample) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5026883A (en) * | 1986-08-21 | 1991-06-25 | Yoshiki Kosuge | Derivatives of scymol sulfate |
| WO1995010283A1 (en) * | 1993-10-12 | 1995-04-20 | J.W. Broadbent Nominees Pty. Ltd. | Treatment of medical disorders associated with free radical formation |
| JP2007063139A (ja) * | 2005-08-29 | 2007-03-15 | Daicho Kikaku:Kk | 皮膚用剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007244325A (ja) * | 2006-03-17 | 2007-09-27 | Daicho Kikaku:Kk | 新しい健康食品 |
-
2012
- 2012-12-14 HU HUE12859788A patent/HUE033800T2/en unknown
- 2012-12-14 AU AU2012321108A patent/AU2012321108B2/en active Active
- 2012-12-14 BR BR112014014968A patent/BR112014014968A2/pt not_active Application Discontinuation
- 2012-12-14 MY MYPI2014001674A patent/MY165030A/en unknown
- 2012-12-14 JP JP2014547630A patent/JP2015500841A/ja active Pending
- 2012-12-14 MX MX2014007659A patent/MX2014007659A/es unknown
- 2012-12-14 SG SG11201403078RA patent/SG11201403078RA/en unknown
- 2012-12-14 CN CN201280063798.3A patent/CN104144689A/zh active Pending
- 2012-12-14 US US14/366,261 patent/US20140364405A1/en not_active Abandoned
- 2012-12-14 RU RU2014126635A patent/RU2624238C2/ru active
- 2012-12-14 WO PCT/AU2012/001543 patent/WO2013090986A1/en not_active Ceased
- 2012-12-14 KR KR1020147020089A patent/KR20140120890A/ko not_active Withdrawn
- 2012-12-14 ES ES12859788.7T patent/ES2632591T3/es active Active
- 2012-12-14 CA CA2859826A patent/CA2859826A1/en not_active Abandoned
- 2012-12-14 PL PL12859788T patent/PL2793897T3/pl unknown
- 2012-12-14 DK DK12859788.7T patent/DK2793897T3/en active
- 2012-12-14 IN IN4693CHN2014 patent/IN2014CN04693A/en unknown
- 2012-12-14 PT PT128597887T patent/PT2793897T/pt unknown
- 2012-12-14 EP EP12859788.7A patent/EP2793897B1/en active Active
-
2014
- 2014-06-12 ZA ZA2014/04348A patent/ZA201404348B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5026883A (en) * | 1986-08-21 | 1991-06-25 | Yoshiki Kosuge | Derivatives of scymol sulfate |
| WO1995010283A1 (en) * | 1993-10-12 | 1995-04-20 | J.W. Broadbent Nominees Pty. Ltd. | Treatment of medical disorders associated with free radical formation |
| JP2007063139A (ja) * | 2005-08-29 | 2007-03-15 | Daicho Kikaku:Kk | 皮膚用剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2632591T3 (es) | 2017-09-14 |
| MY165030A (en) | 2018-02-28 |
| CA2859826A1 (en) | 2013-06-27 |
| HK1199818A1 (en) | 2015-07-24 |
| HUE033800T2 (en) | 2018-01-29 |
| JP2015500841A (ja) | 2015-01-08 |
| KR20140120890A (ko) | 2014-10-14 |
| EP2793897B1 (en) | 2017-04-12 |
| RU2014126635A (ru) | 2016-02-10 |
| WO2013090986A1 (en) | 2013-06-27 |
| DK2793897T3 (en) | 2017-07-31 |
| PL2793897T3 (pl) | 2017-10-31 |
| AU2012321108A1 (en) | 2013-07-04 |
| AU2012321108B2 (en) | 2015-07-09 |
| NZ625852A (en) | 2015-07-31 |
| EP2793897A1 (en) | 2014-10-29 |
| CN104144689A (zh) | 2014-11-12 |
| BR112014014968A2 (pt) | 2017-06-13 |
| MX2014007659A (es) | 2014-11-14 |
| SG11201403078RA (en) | 2014-07-30 |
| ZA201404348B (en) | 2016-10-26 |
| EP2793897A4 (en) | 2015-04-08 |
| PT2793897T (pt) | 2017-07-17 |
| US20140364405A1 (en) | 2014-12-11 |
| IN2014CN04693A (enExample) | 2015-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7201660B2 (ja) | 皮膚の弛緩と身体の輪郭を改善するための組成物および方法 | |
| US6437002B1 (en) | Agent for preventing and treating skin diseases | |
| JP2015508094A (ja) | Ｄｇｌａ、１５−ｏｈｅｐａ、及び／又は１５−ｈｅｔｒｅを含む医薬組成物並びにこれを使用する皮脂生成の低減法 | |
| KR20150025286A (ko) | 피토스핑고신-1-포스페이트 또는 그 유도체를 포함하는 아토피 또는 피부상처 치료 또는 예방용 조성물 | |
| AU2012245960B2 (en) | Suspension type topical formulations comprising cyclic depsipeptide | |
| CN105263469A (zh) | 包含比马前列素的局部组合物和利用其刺激毛发生长的方法 | |
| JP6725207B2 (ja) | 皮膚色素沈着抑制剤 | |
| CN106061474B (zh) | 用类单萜治疗脱发的方法 | |
| KR101186130B1 (ko) | 니코틴산 아데닌 디뉴클레오티드 인산 또는 그의 유도체를 포함하는 약학적 또는 화장료 조성물 | |
| JP2024053124A (ja) | 外用組成物 | |
| JP5355913B2 (ja) | レチノイドとβ−アミノイソ酪酸誘導体とを含む組成物 | |
| WO2015001891A1 (ja) | コラーゲン産生促進用、エラスチン産生促進用および／またはケラチノサイト遊走促進用組成物およびその利用 | |
| RU2624238C2 (ru) | Лечение себореи | |
| JP6656890B2 (ja) | フィラグリン産生促進剤 | |
| US20190255070A1 (en) | Pharmaceutical compositions | |
| JP2017214343A (ja) | 尋常性ざ瘡治療剤 | |
| CN104717964A (zh) | 用于预防和/或治疗毛发失调的伊罗替罗及其组合物 | |
| EA039464B1 (ru) | Композиции для местного применения для ухода за кожей | |
| HK1199818B (en) | Treatment of seborrhoea | |
| NZ625852B2 (en) | Treatment of seborrhoea | |
| JPH10245393A (ja) | トリテルペン類を含有する組成物 | |
| JP2023509971A (ja) | 毛髪成長の刺激 | |
| MX2007006059A (es) | Composicion de crema desmanchadora de piel. | |
| WO2018123003A1 (ja) | メラニン生成抑制用の外用組成物 | |
| KR20150066810A (ko) | 여드름 예방 및 개선용 조성물 |